Loading
Turned anaplastic thyroid cancer, once measured in months, into a treatable disease with BRAF-targeted therapy and neoadjuvant strategies.
Maria Cabanillas led the anaplastic thyroid cancer work within the ROAR basket trial that won dabrafenib plus trametinib approval for BRAF V600E-mutant disease, and pioneered neoadjuvant BRAF/MEK inhibition to make previously unresectable tumours operable, which has raised one-year survival in her centre's series from near zero to above 50%. She leads the anaplastic thyroid cancer programme at MD Anderson.
Shares ROAR (anaplastic thyroid cancer cohort), MD Anderson Cancer Center, BRAF, Thyroid cancer.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tag thyroid.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tag thyroid.
Shares Thyroid cancer, Small-molecule kinase inhibitors and the tag thyroid.
Shares MD Anderson Cancer Center, BRAF, Small-molecule kinase inhibitors and the tag braf.
Shares MD Anderson Cancer Center, Small-molecule kinase inhibitors.
Shares BRAF, Thyroid cancer and the tag braf.
Shares Thyroid cancer and the tag thyroid.